Alkermes
NEWS
The U.S. FDA is starting off the summer months with a busy week after the Memorial Day holiday in the U.S. Here’s a look.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.
The two companies received Complete Response Letters from the FDA this week, along with Sanofi.
Here’s a look at some of the upcoming target action dates on the U.S. FDA’s calendar.
Shares of Alkermes were up more than 12% in pre-market trading after the Ireland-based company announced late Friday that its schizophrenia drug ALKS 3831 was overwhelmingly supported by an advisory committee for the U.S. Food and Drug Administration.
The assessment does point to a path for approval, however FDA staff do raise some concerns about the fact that the drug’s makeup includes an opioid antagonist.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
JOBS
IN THE PRESS